June 25, 2022

Medical Trend

Medical News and Medical Resources

UK MHRA accepts marketing application for almetinib

UK MHRA accepts marketing application for almetinib



 

UK MHRA accepts marketing application for almetinib.


On June 14, EQRx, Inc announced that the UK Medicines and Health Products Regulatory Agency (MHRA) has accepted a Marketing Authorization Application (MAA) for the third-generation EGFR tyrosine kinase inhibitor (TKI) almetinib for the treatment of adults First-line treatment of locally advanced or metastatic non-small cell lung cancer.

The application is primarily based on data from the pivotal Phase III AENEAS trial, which is the first time EQRx has submitted a marketing application to a regulatory agency.

 

UK MHRA accepts marketing application for almetinib

 

AENEAS (NCT03849768) is a randomized, double-blind, multicenter Phase III study to evaluate the efficacy and safety of almetinib versus gefitinib as first-line treatment for adults with locally advanced or metastatic EGFR-mutant non-small cell lung cancer sex.

Conducted by Hansoh Pharmaceuticals, the study enrolled 429 patients who were randomized to receive almetinib (n=214) or gefitinib (n=215). The study met its primary endpoint, data have been published in the Journal of Clinical Oncology, and data on almetinib activity in CNS metastases were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

 

UK MHRA accepts marketing application for almetinib

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org